MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1021/acsptsci.6c00044

Медицинская библиотека · ACS pharmacology & translational science · 2026

PhiKan 083 Inhibits MYCN Expression in Liver Cancer Cells Independent of p53 Pathways.

Xu Yali, Mishra Hricha, Takahashi Masataka, Nishimura Hajime, Suenaga Yusuke, Yu Wenkui, Hippo Yoshitaka, Suzuki Harukazu, Qin Xian-Yang

СтатьяПеревод пока не подготовлен

Аннотация

MYCN is a key oncogenic driver in hepatocellular carcinoma (HCC) and a therapeutic challenge due to the historical undruggability of MYC transcription factors (TFs). Using a high-throughput MYCN promoter-luciferase reporter, we identified PhiKan 083 (PK83), a small molecule previously recognized as a mutant p53 activator, that dose-dependently suppresses MYCN expression in HCC cells. PK83 impaired the proliferation and survival of MYCN-high HCC cells, inducing DNA damage, apoptosis, and loss of clonogenic and spheroid growth potential, while sparing MYCN-low HCC cells and normal hepatocytes. Structure-activity analysis revealed that polar, hydrogen-bond-capable substituents on PK83's tricyclic scaffold are critical for its activity. Although PK83 broadly activates p53 signaling, its cytotoxicity in MYCN-high cells is not strictly dependent on intact p53, as confirmed in p53-knockout systems. Transcriptome profiling and pathway analysis demonstrated robust suppression of MYC/MYCN targets along with modulation of pathways linked to stress, differentiation, and metabolism. In primary HCC tumors, PK83-downregulated TFs, including oncogenic TFs ZMIZ1 and TARBP1, positively correlated with MYCN, whereas upregulated stress-responsive TFs ATF3 and FOSL2 showed a negative correlation. These findings suggest that PK83 suppresses MYCN expression and preferentially affects MYCN-high HCC cells in a p53-independent manner, warranting further preclinical investigation of PK83 and related compounds in MYCN-associated cancers.

Для цитирования: Xu Yali, Mishra Hricha, Takahashi Masataka, Nishimura Hajime, Suenaga Yusuke, Yu Wenkui, Hippo Yoshitaka, Suzuki Harukazu, Qin Xian-Yang. PhiKan 083 Inhibits MYCN Expression in Liver Cancer Cells Independent of p53 Pathways.. ACS pharmacology & translational science. 2026. DOI: 10.1021/acsptsci.6c00044.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.